Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes-Reference-Cited by-同舟云学术

Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes

Published:2022-10 Issue: Volume:206 Page:105386
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Desmares Manon,Delphin Marion,Chardès Brieux,Pons Caroline,Riedinger Juliette,Michelet Maud,Rivoire Michel,Verrier Bernard,Salvetti Anna,Lucifora Julie,Durantel David

Funder

Agence Nationale de la Recherche

Institut National de la Santé et de la Recherche Médicale

Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Labex

Centre National de la Recherche Scientifique

Université de Lyon

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference46 articles.

1. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: a meta-analysis;Abdrakhman;Antivir. Res.,2021

2. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Re-modelling of Antiviral and Regulatory Mediators;Amin,2020

3. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial;Bazinet;Lancet Gastroenterol. hepatol.,2017

4. Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy;Bazinet;Gastroenterology,2020

5. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome;Belloni;J. Clin. Invest.,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel mechanistic insights – A brand new Era for anti-HBV drugs;European Journal of Medicinal Chemistry;2024-12

2. The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis;PLOS Pathogens;2024-06-27

3. A Synthetic Multivalent Lipopeptide Derived from Pam3CSK4 with Irreversible Influenza Inhibition and Immuno‐Stimulating Effects;Small;2024-03-04

4. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA;Viruses;2023-11-25

5. TLR pathway signaling molecules in burbot (Lota lota): molecular characterization, basal expression, and their response to Poly(I:C);Fish & Shellfish Immunology;2023-09